New drug aims to heal hearts after major attack

NCT ID NCT07586865

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called NL005 in people who have had a severe type of heart attack (STEMI) and undergone emergency artery-opening treatment. The goal is to see if NL005 can reduce permanent heart muscle damage. Participants will receive either NL005 or a placebo daily for 7 days and be monitored for a year with scans and checkups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
recombinant human thymosin beta 4 (NL005)
What this could lead to
If it works, this could lead to a treatment that reduces permanent heart muscle damage after a severe heart attack, potentially improving recovery and lowering the risk of heart failure.
What could go wrong
This is an early Phase IIc trial with only 189 participants, so results may not apply to everyone. The drug is experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)

    Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.